--- title: "由于超级细菌治疗的后期试验取得进展，Armata Pharmaceuticals 的股票大幅上涨" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/293234406.md" description: "Armata Pharmaceuticals 的股价在宣布其 AP-SA02 的第三阶段试验关键里程碑后上涨了 18%。该疗法是一种针对超级细菌（如 MRSA）的噬菌体疗法。公司已向 FDA 提交最终测试计划，并在其洛杉矶设施完成了工程运行。Armata 从美国国防部获得了额外的 250 万美元资金，使总融资达到 2870 万美元。首席执行官 Deborah Birx 强调，推进第三阶段研究仍然是首要任务" datetime: "2026-07-20T15:29:45.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/293234406.md) - [en](https://longbridge.com/en/news/293234406.md) - [zh-HK](https://longbridge.com/zh-HK/news/293234406.md) generator: "portal-rs" --- # 由于超级细菌治疗的后期试验取得进展，Armata Pharmaceuticals 的股票大幅上涨 By Anvee Bhutani Armata Pharmaceuticals shares rose Monday after the company said it took a major step toward the launch of a late-stage trial for its experimental superbug treatment, AP-SA02. In morning trading, Armata shares were up 18% at $5.31. The biotechnology company said it achieved key clinical, regulatory and manufacturing milestones supporting the planned launch of a Phase 3 trial of the treatment, and submitted its final testing plans to the U.S. Food and Drug Administration. The bacteriophage therapy targets so-called superbugs such as MRSA. The company also said it completed four engineering runs of AP-SA02 at its Los Angeles facility. Production of clinical trial material will be the next manufacturing step ahead of the planned Phase 3 study. Armata said it remains on track to begin the pivotal Phase 3 superiority study in the second half of 2026. The trial will evaluate AP-SA02 as an add-on treatment for severe Staphylococcus aureus bacteremia, including MRSA, and is intended to support a future biologics license application. Separately, the company said it recently received an additional $2.5 million in funding from the U.S. Defense Department, bringing total funding under the award to $28.7 million. The new funding will support preparations for the Phase 3 trial, while Armata said it is also pursuing additional financing sources to fund the study. Chief Executive Deborah Birx said advancing AP-SA02 into Phase 3 remains the company's top priority. Armata also promoted David House to chief financial officer from senior vice president of finance and principal financial officer. Write to Anvee Bhutani at anvee.bhutani@wsj.com (END) Dow Jones Newswires July 20, 2026 11:19 ET (15:19 GMT) Copyright (c) 2026 Dow Jones & Company, Inc. ### 相关股票 - [ARMP.US](https://longbridge.com/zh-CN/quote/ARMP.US.md) ## 相关资讯与研究 - [Armata Pharmaceuticals｜8-K：2026 财年 Q2 营收 2.51 百万美元超过预期](https://longbridge.com/zh-CN/news/295708484.md) - [Armata Pharmaceuticals 表示，吸入式噬菌体候选药物 AP-PA02 已在囊性纤维化和支气管扩张患者中完成了第二阶段临床试验](https://longbridge.com/zh-CN/news/297902417.md) - [Arm 的首席执行官表示，人工智能有可能治愈癌症。然而，数据中心正在成为一个瓶颈](https://longbridge.com/zh-CN/news/298273784.md) - [SRRK：ISEMBYLD 获得 FDA 批准，成为首个肌肉靶向的 SMA 疗法，并在美国推出](https://longbridge.com/zh-CN/news/298774302.md) - [Editas Medicine 计划在 2026 年开始对患者进行 LDL 基因编辑疗法的给药](https://longbridge.com/zh-CN/news/298778598.md) --- > **免责声明: 本文仅供参考，不构成任何投资建议。**